Starton Holdings, a Phase 2 developer of controlled release formulations for an approved cancer drug, lowered the proposed deal size for its upcoming IPO on Tuesday. The Paramus, NJ-based company now plans to raise $30 million by offering 5 million shares at a ...read more
WhiteHawk Minerals, which owns natural gas mineral and royalty interests in the Marcellus and Haynesville Shales, raised $200 million by offering 7.7 million shares at $26, within the $25 to $27 range. The company offered 0.8 million more shares than...read more
Parabilis Medicines, a clinical-stage biotech developing engineered peptide therapies for cancer, raised the proposed deal size for its upcoming IPO on Tuesday. The Cambridge, MA-based company now plans to raise $600 million by offering 33.3 million shares at...read more
Phase 2 oncology drug developer Starton Holdings decreases shares offered by 25% ahead of $30 million IPO
Starton Holdings, a Phase 2 developer of controlled release formulations for an approved cancer drug, lowered the proposed deal size for its upcoming IPO on Tuesday. The Paramus, NJ-based company now plans to raise $30 million by offering 5 million shares at a ...read more
Natural gas mineral and royalty business WhiteHawk Minerals prices upsized IPO at $26 midpoint
WhiteHawk Minerals, which owns natural gas mineral and royalty interests in the Marcellus and Haynesville Shales, raised $200 million by offering 7.7 million shares at $26, within the $25 to $27 range. The company offered 0.8 million more shares than...read more
Cancer biotech Parabilis Medicines ups shares offered by 33% ahead of $600 million IPO
Parabilis Medicines, a clinical-stage biotech developing engineered peptide therapies for cancer, raised the proposed deal size for its upcoming IPO on Tuesday. The Cambridge, MA-based company now plans to raise $600 million by offering 33.3 million shares at...read more